Recent News

• 08.06.2026 - Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
• 07.23.2026 - Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
• 05.20.2026 - Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
• 05.11.2026 - Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
• 04.02.2026 - Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
• 02.06.2026 - Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
• 01.23.2026 - Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
• 12.11.2025 - Immunovant Announces Pricing of $550 Million Common Stock Financing
• 11.10.2025 - Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025
• 10.27.2025 - Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Recent Filings

• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - 8-K Current report
• 08.06.2026 - EX-99.1 EX-99.1
• 07.24.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.24.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.24.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.22.2026 - ARS Annual Report to Security Holders
• 07.22.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 07.22.2026 - DEF 14A Other definitive proxy statements
• 07.10.2026 - 4 Statement of changes in beneficial ownership of securities